2023: A New Chapter in FDA Drug Approvals - A Resurgence of Innovation

January 11, 2024

Medical professionals working together at a desk

The year 2023 unveiled an eventful chapter in FDA drug approvals, heralding a resurgence of innovation after a brief decline. This period represented not just a numerical rebound but a meaningful shift in strategies and approaches, reflecting a commitment to elevating patient care and bolstering scientific advancement. Indeed, FDA had a robust bounce-back this year, with a staggering 72 novel agents approved by the FDA (55 novel drugs and 17 novel biologics), signaling a substantial leap from the preceding year (in 2022, 50 total, 37 novel drug approvals and 13 biologics approvals). This surge in approvals echoed across various therapeutic areas, underscoring the agency's dedication to addressing diverse medical needs.

Key FDA Approvals and Adjustments

Landmark breakthroughs illuminated the power of scientific innovation. Tirzepatide, a dual-acting medication, offers a new hope for millions grappling with both type 2 diabetes and weight management. Data points indicate that over 5 million individuals suffer from both conditions in the US alone, and Tirzepatide's approval represents a potential breakthrough with its efficacy exceeding existing drugs. For patients battling age-related macular degeneration, Iveric Bio's aptamer, Izervay, a first-in-class therapy, charted a new course. And importantly, the underserved community battling the rare CHAPLE disease, with an estimated global population less than 100, will now have the newly approved mAb, Veopoz, as a treatment option. These approvals exemplify the FDA's unwavering commitment to tackling unmet medical needs, regardless of patient numbers.

However, 2023 wasn't solely about the quantity of approvals. The Aduhelm controversy of 2021 cast a long shadow, prompting the FDA to tighten the reins on accelerated approvals. The new paradigm emphasized robust confirmatory data and demonstrable clinical benefit. Indeed, from ongoing media criticism, to FDA draft guidance on post-market requirements, to congressional spending vehicles, 2023 saw a flurry of signals, all suggesting that accelerated approvals are under increased scrutiny.

Focus Shift: Orphan Drugs and First-in-Class Therapies

On the other hand, a subtle but significant shift in focus permeated the landscape, particularly with regards to number of orphan drug and first-in-class therapies. Indeed, orphan drug approvals have steadily increased in recent years, with 2023 seeing the approval of 37 orphan drugs, representing a significant portion of the overall approvals. These approvals resonate with the FDA's unwavering commitment to fostering innovation and addressing unmet needs, even in niche corners of the medical world.

Initiatives Driving Change

Initiatives like Project Orbis, a global collaboration aimed at harmonizing cancer drug reviews, promised to usher in a new era of expedited access to revolutionary treatments for patients across the globe. The increasing emphasis on including overall survival data in cancer trials further solidified the FDA's commitment to ensuring that new drugs translate into tangible improvements in patient outcomes. Exploring the feasibility of single-arm trials for specific scenarios, like rare diseases and gene therapies, offered a glimmer of hope for patients desperately awaiting life-saving solutions.

Looking Ahead: Navigating Innovation Responsibly

As we peer into the future, 2023 serves as a pivotal turning point. The horizon looms large with promises of personalized medicine, gene therapies, and AI-driven drug discovery. However, this exciting vista must be traversed with a sense of responsibility and rigor. The lessons learned from tightened approval processes over recent years and evolving regulatory strategies serve as guiding lights, ensuring that innovation flourishes within a framework of robust evidence and unwavering patient safety.

2023 will be remembered as a year of navigating a turbulent tide, balancing hope with caution, and striving to ensure that the tide of scientific progress ultimately washes ashore, delivering safe and effective treatments to those who need it most.

Seeking FDA Approval? Partner with ProPharma for Expert Guidance

Navigating the FDA approval process can be complex. Whether you're a pharmaceutical company seeking approval for a new drug or a biotech firm aiming for biologics approval, ProPharma's expertise can be your guiding light.

Connect with ProPharma Today

Do you need assistance with your FDA approval journey? Contact ProPharma's team of seasoned professionals specializing in regulatory affairs, compliance, and strategy. Let us help you navigate the intricate landscape of FDA approvals, ensuring compliance, and success for your innovative solutions.


November 3, 2020

Why Drug Approvals Are Never Slam Dunks

It's the FDA, Not the NBA Aside from being a spectacular thing to watch, the slam dunk is the highest percentage shot a basketball player can take. The likelihood of getting the ball in the basket is...

Woman typing on a laptop next to a microscope in a medical laboratory.

January 26, 2024

Illuminating FDA's 2023 BLA Approvals: A Comparative Analysis

The FDA's Biologics License Application (BLA) approvals in 2023 have marked a significant chapter in medical innovation, embodying precision and transformative therapies. A closer examination of the...

February 15, 2018

FDA Steps up its Game on Generic Drugs: The Story Behind the Recent Focus on Generic Products

Throughout 2017, the FDA focused its attention on the regulation of generic drug products. In 2015, the Agency issued only two generic-related guidance documents. In 2016, there were seven. In 2017,...